锂精粉业务2025年预计营收超2亿元 尔康制药海外战略布局初显成效

Group 1 - The company expects a net profit attributable to shareholders of between -325 million to -385 million yuan for the fiscal year 2025, primarily impacted by asset impairment losses [1] - The company's main business has shown steady growth compared to the same period in 2024, benefiting from the operation of the lithium ore beneficiation plant project in Nigeria, with expected revenue from lithium concentrate business exceeding 200 million yuan [1] - The cash flow from operating activities has significantly increased compared to the same period in 2024, indicating a healthy operational status [1] Group 2 - The company is accelerating its industrial layout in Africa, investing a total of 18 million dollars in comprehensive formulation and injection production projects in Tanzania and Nigeria [2] - The ongoing deepening of China-Africa cooperation provides significant opportunities for Chinese companies to expand overseas, aligning with the company's strategy to enhance its presence in the African renewable energy and healthcare sectors [2] - The company is expected to solidify its long-term development foundation as mining project capacities continue to be released and pharmaceutical manufacturing bases are established, with future performance likely to return to a growth trajectory [2]